Back to Research Hub
Halozyme Therapeutics, Inc.
HALO
$71.48+0.75 (+1.06%)
Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the…
StreetsValue research for Halozyme Therapeutics, Inc. (HALO)
Members get the full report for Halozyme Therapeutics, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.